The $9 central target is the arithmetic mean of ten attributable analyst price targets, not an official published consensus. The full range is wide, from $3.85 to $14, and the average works out to roughly $8.99 before rounding. Individual targets include Canaccord Genuity's $14 (Buy, September 2026), Piper Sandler's $10 (Buy), Jefferies' $10 (Buy), RBC Capital's $9 (Buy), Baird's $9 (Outperform), Citizens JMP's $8 (Market Outperform), UBS's $8 (Buy), Oppenheimer's $7 (Buy), H.C. Wainwright's $11 (Buy), and Bernstein's $3.85 (Market Perform).
The dispersion matters more than the average. Bulls emphasize that the ALPHA3 interim futility analysis showed cema-cel achieving a 58.3% minimal residual disease (MRD) clearance rate versus 16.7% for observation, which they see as de-risking an "off-the-shelf" CAR T (chimeric antigen receptor T-cell) platform. More cautious analysts, such as Bernstein, keep materially lower targets tied to clinical-execution risk, durability of response, and funding. J.P. Morgan upgraded ALLO from Underweight to Neutral in April 2026, reflecting a slightly more constructive but still guarded stance.
Allogene Therapeutics, Inc. (ALLO) is a clinical-stage immuno-oncology company developing allogeneic CAR T therapies for cancer and autoimmune disease. With the stock trading near $1.23 against a 52-week range of roughly $1.04 to $4.46, the gap to $9 represents an upside of about 630%. That is a very large move and would require not only favorable clinical data but also a substantial re-rating of a company that currently generates minimal revenue.
The path runs primarily through cema-cel, the lead candidate in the pivotal Phase 2 ALPHA3 trial for first-line large B-cell lymphoma, plus ALLO-329 in autoimmune disease. Management has indicated a cash runway into 2029, which reduces near-term dilution risk but does not remove the binary nature of the readouts ahead.
The most important catalyst is the ALPHA3 trial itself. The April 2026 interim futility analysis reported a 58.3% MRD clearance rate for cema-cel versus 16.7% for observation, with a favorable safety profile and potential for outpatient use. If final efficacy data confirm this signal, cema-cel could target a first-line lymphoma market management has sized in the billions of dollars. Broadening adoption of MRD testing across oncology, and the U.S. Food and Drug Administration's May 2026 approval of an MRD-guided therapy in bladder cancer, lend credibility to the trial's design. ALLO-329, with proof-of-concept data expected, offers a second, non-oncology growth avenue in autoimmune disease.
Clinical-stage biotechs carry binary risk: a failed or mixed readout could compress the stock sharply. Allogeneic CAR T therapies still face questions about durability of response, manufacturing consistency, and competition from autologous CAR T products. The company continues to post significant net losses and burns cash, and while the runway extends into 2029, future dilution or financing remains possible. The wide $3.85-to-$14 target range itself signals that analysts disagree fundamentally about whether the platform will translate into commercial success.
ALLO trades near the bottom of its 52-week range, with a recent low around $1.04 acting as a key support level and the $1.00 mark serving as a psychological floor. On the upside, the stock would need to reclaim multiple resistance levels, with the 52-week high near $4.46 representing the first major structural hurdle well before any approach toward $9. The long-term trend remains downward, with the shares having declined steadily through late 2026 and trading well below their 20-day average.
Analyst price targets typically reflect a roughly 12-month research horizon, though firms rarely state a precise date and timelines differ. Investors should monitor the next quarterly earnings report, updated cash guidance, progress on ALPHA3 enrollment and any interim event-free survival analysis, ALLO-329 proof-of-concept data, and analyst revisions to ratings and targets. Regulatory and MRD-adoption developments in oncology also matter, as do broader biotech sector conditions and interest-rate expectations.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile name like ALLO, this can help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual scanning. Explore the signals to see how AI is tracking this and other tickers.
The $9 central target is the average of ten analyst price targets spanning $3.85 to $14, implying a very large move of roughly 630% from a recent price near $1.23. Reaching that level would likely require definitive success for cema-cel in ALPHA3, progress in ALLO-329, and a meaningful re-rating of the entire allogeneic CAR T platform. The strongest support comes from encouraging interim MRD data and a cash runway into 2029; the principal obstacles are binary clinical risk, ongoing losses, and a wide analyst divergence of opinion. Investors should weigh these factors and monitor upcoming data readouts and financial updates rather than treating the average target as a forecast or guarantee.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALLO | 1D Price Change % | ||
|---|---|---|---|---|
| ALLO | 100% | -3.41% | ||
| EDIT - ALLO | 49% Loosely correlated | -4.99% | ||
| AXON - ALLO | 44% Loosely correlated | +4.26% | ||
| RCKT - ALLO | 43% Loosely correlated | +1.22% | ||
| ARRY - ALLO | 43% Loosely correlated | +9.94% | ||
| FDMT - ALLO | 43% Loosely correlated | +4.25% | ||
More | ||||